Current progress in CAR‑T cell therapy for tumor treatment (Review)
- Authors:
- Lei Chen
- Ting Xie
- Bing Wei
- Da-Lin Di
-
Affiliations: Department of Hematology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Immunology, Weifang Medical University, Weifang, Shandong 261053, P.R. China - Published online on: August 25, 2022 https://doi.org/10.3892/ol.2022.13478
- Article Number: 358
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rafei H, Kantarjian HM and Jabbour EJ: Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 60:2606–2621. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, et al: Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European society for blood and marrow transplantation (EBMT) and the American society for blood and marrow transplantation (ASBMT). Bone Marrow Transplant. 54:1868–1880. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Larson RC and Maus MV: Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 21:145–161. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M and Teh B: CAR-T cell therapy and infection: A review. Expert Rev Anti Infect Ther. 19:749–758. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A and Sadelain M: CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 24:731–738. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gross G, Waks T and Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Eshhar Z, Waks T, Gross G and Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 90:720–724. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Siegler EL and Wang P: Preclinical models in chimeric antigen receptor-engineered T-cell therapy. Hum Gene Ther. 29:534–546. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, et al: Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: A systematic review and meta-analysis. Transfus Med Rev. 33:98–110. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Roselli E, Frieling JS, Thorner K, Ramello MC, Lynch CC and Abate-Daga D: CAR-T engineering: Optimizing signal transduction and effector mechanisms. BioDrugs. 33:647–659. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hu W, Huang X, Huang X, Chen W, Hao L and Chen Z: Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection. Biomed Pharmacother. 118:1093332019. View Article : Google Scholar : PubMed/NCBI | |
|
Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, et al: An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 12:eaap97772019. View Article : Google Scholar : PubMed/NCBI | |
|
Abramson JS: Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma. Transfus Med Rev. 34:29–33. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 15:1145–1154. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD and Hirano N: A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 24:352–359. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lin H, Cheng J, Mu W, Zhou J and Zhu L: Advances in universal CAR-T cell therapy. Front Immunol. 12:7448232021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Lin Q, Song Y and Liu D: Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 11:1322018. View Article : Google Scholar : PubMed/NCBI | |
|
Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, et al: Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 9:eaaj20132017. View Article : Google Scholar : PubMed/NCBI | |
|
Cho JH, Collins JJ and Wong WW: Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 173:1426–1438.e11. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Xu B, Wu Z, Bo J, Tong C, Chen D, Wang J, Wang H, Wang Y and Han W: Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. Eur J Immunol. 51:2513–2521. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Depil S, Duchateau P, Grupp SA, Mufti G and Poirot L: ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges. Nat Rev Drug Discov. 19:185–199. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Martino M, Alati C, Canale FA, Musuraca G, Martinelli G and Cerchione C: A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 22:21502021. View Article : Google Scholar : PubMed/NCBI | |
|
Wudhikarn K, Flynn JR, Rivière I, Gönen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, et al: Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 138:531–543. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, Marcoulis M, White KL, Whitman JD, Bapat SP, et al: Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL. Cancer Discov. 11:2032–2049. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, et al: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 13:302020. View Article : Google Scholar : PubMed/NCBI | |
|
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5:177ra382013. View Article : Google Scholar : PubMed/NCBI | |
|
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 6:224ra252014. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, Wei G, Han L, Wang H, Yu S, et al: CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 27:2764–2772. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Raetz EA and Teachey DT: T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016:580–588. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, et al: Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial. J Clin Oncol. 39:3340–3351. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, Wang L, Wang Q, Jin D, Li J and Huang X: Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: First-in-human phase 1 clinical trial. Blood. 140:321–334. 2022.PubMed/NCBI | |
|
Dai HP, Cui W, Cui QY, Zhu WJ, Meng HM, Zhu MQ, Zhu XM, Yang L, Wu DP and Tang XW: Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. Biomark Res. 10:62022. View Article : Google Scholar : PubMed/NCBI | |
|
Xie L, Ma L, Liu S, Chang L and Wen F: Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. Int Immunopharmacol. 96:1077312021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, You F, Xiang S, Wang Y, Li Y, Meng H, An G, Zhang T, Li Z, Jiang L, et al: Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies. Am J Cancer Res. 11:5263–5281. 2021.PubMed/NCBI | |
|
Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E and Campana D: Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 1:2348–2360. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chong EA, Ruella M and Schuster SJ; Lymphoma Program Investigators at the University of Pennsylvania, : Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 384:673–674. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, et al: In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas. Mol Ther. 26:2727–2737. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bunse M, Pfeilschifter J, Bluhm J, Zschummel M, Joedicke JJ, Wirges A, Stark H, Kretschmer V, Chmielewski M, Uckert W, et al: CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. Nat Commun. 12:2402021. View Article : Google Scholar : PubMed/NCBI | |
|
Yin Z, Zhang Y and Wang X: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomark Res. 9:582021. View Article : Google Scholar : PubMed/NCBI | |
|
Mihăilă RG: Chimeric antigen receptor-engineered T-cells-a new way and era for lymphoma treatment. Recent Pat Anticancer Drug Discov. 14:312–323. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shah NN, Maatman T, Hari P and Johnson B: Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol. 9:1462019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu B, Jiang T and Liu D: BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 13:1252020. View Article : Google Scholar : PubMed/NCBI | |
|
Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, et al: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 128:1688–1700. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ferment B and Arnulf B: CAR-T cells immunotherapy in multiple myeloma: Present and future. Bull Cancer. 108 (10 Suppl):S65–S72. 2021.(In French). View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, et al: Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA. 116:9543–9551. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE and Chen YY: Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 11:22832020. View Article : Google Scholar : PubMed/NCBI | |
|
Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen RWJ, et al: Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin Cancer Res. 25:4014–4025. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Springuel L, Lonez C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, Prenen H, Hendlisz A, Shaza L, Carrasco J, et al: Chimeric antigen receptor-T cells for targeting solid tumors: Current challenges and existing strategies. Biodrugs. 33:515–537. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, Mellor AL, Wang W and Wu S: Adoptive CD8+ T cell therapy against cancer: Challenges and opportunities. Cancer Lett. 462:23–32. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Irving M, Vuillefroy de Silly R, Scholten K, Dilek N and Coukos G: Engineering chimeric antigen receptor T-cells for racing in solid tumors: Don't forget the fuel. Front Immunol. 8:2672017. View Article : Google Scholar : PubMed/NCBI | |
|
Junttila MR and de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hajari Taheri F, Hassani M, Sharifzadeh Z, Behdani M, Arashkia A and Abolhassani M: T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. IUBMB Life. 71:1259–1267. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Akbari P, Huijbers EJM, Themeli M, Griffioen AW and van Beijnum JR: The tumor vasculature an attractive CAR T cell target in solid tumors. Angiogenesis. 22:473–475. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Balakrishnan A, Rajan A, Salter AI, Kosasih PL, Wu Q, Voutsinas J, Jensen MC, Plückthun A and Riddell SR: Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors. Clin Cancer Res. 25:7506–7516. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O'Connor RS, Minutolo NG, Casado-Medrano V, Lopez G, Matsuyama T and Powell DJ: J: CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 12:8772021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Li F, Cao J, Wang X, Cheng H, Qi K, Wang G, Xu K, Zheng J, Fu YX and Yang X: A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med. 13:eaba73082021. View Article : Google Scholar : PubMed/NCBI | |
|
Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, Powell DJ Jr and Coukos G: T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res. 3:68–84. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, et al: TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res. 78:489–500. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida T and Kataoka H: Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers (Basel). 11:13392019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang P, Qin W, Liu T, Jiang D, Cui L, Liu X, Fang Y, Tang X, Jin H and Qian Q: PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma. Immunobiology. 225:1518502020. View Article : Google Scholar : PubMed/NCBI | |
|
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J and Zhao X: Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 7:1813–1823. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yazdanifar M, Zhou R, Grover P, Williams C, Bose M, Moore LJ, Wu ST, Maher J, Dreau D and Mukherjee AP: Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells. 8:10702019. View Article : Google Scholar : PubMed/NCBI | |
|
Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, Sun MY, Cao X, Wang Y, Guo L, Indig IH, et al: Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neuro Oncol. 21:1436–1446. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mao Y, Fan W, Hu H, Zhang L, Michel J, Wu Y, Wang J, Jia L, Tang X, Xu L, et al: MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol. 12:1062019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, et al: Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 25:1248–1258. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Abbott RC, Verdon DJ, Gracey FM, Hughes-Parry HE, Iliopoulos M, Watson KA, Mulazzani M, Luong K, D'Arcy C, Sullivan LC, et al: Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma. Clin Transl Immunology. 10:e12832021. View Article : Google Scholar : PubMed/NCBI | |
|
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 9:eaaa09842017. View Article : Google Scholar : PubMed/NCBI | |
|
Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, et al: CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 37:1049–1058. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, Hogarty MD, Barrett DM, Shimada H and Asgharzadeh S: Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 12:5112021. View Article : Google Scholar : PubMed/NCBI | |
|
Porter D, Frey N, Wood PA, Weng Y and Grupp SA: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 11:352018. View Article : Google Scholar : PubMed/NCBI | |
|
Nagle SJ, Murphree C, Raess PW, Schachter L, Chen A, Hayes-Lattin B, Nemecek E and Maziarz RT: Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 96:455–461. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C and Dreger P: Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 32:34–48. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z and Han W: Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 6:42018. View Article : Google Scholar : PubMed/NCBI | |
|
Szenes V and Curran KJ: Utilization of CAR T cell therapy in pediatric patients. Semin Oncol Nurs. 35:1509292019. View Article : Google Scholar : PubMed/NCBI | |
|
Koristka S, Ziller-Walter P, Bergmann R, Arndt C, Feldmann A, Kegler A, Cartellieri M, Ehninger A, Ehninger G, Bornhäuser M and Bachmann MP: Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. Cancer Immunol Immunother. 68:1401–1415. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C and Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276:1719–1724. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM and Rooney CM: An inducible caspase 9 safety switch for T-cell therapy. Blood. 105:4247–4254. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gerber HP, Sibener LV, Lee LJ and Gee M: Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochem Pharmacol. 168:275–284. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fedorov VD, Themeli M and Sadelain M: PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 5:215ra1722013. View Article : Google Scholar : PubMed/NCBI | |
|
Kloss CC, Condomines M, Cartellieri M, Bachmann M and Sadelain M: Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 31:71–75. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, Liu X, Li X, Zhou Y, Song Z, Zhang J, Shi B and Wang J: Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. Oncoimmunology. 10:19591022021. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson FP and Berns JS: Tumor lysis syndrome: New challenges and recent advances. Adv Chronic Kidney Dis. 21:18–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Miao L, Zhang Z, Ren Z and Li Y: Reactions related to CAR-T cell therapy. Front Immunol. 12:6632012021. View Article : Google Scholar : PubMed/NCBI | |
|
Gust J, Ponce R, Liles WC, Garden GA and Turtle CJ: Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 11:5770272020. View Article : Google Scholar : PubMed/NCBI | |
|
Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, Hartmann M, Meyer J, Hartmann S, Hansmann ML, Fehse B and von Laer D: Resistance of mature T cells to oncogene transformation. Blood. 112:2278–2286. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, Denizio JE, Reddy S, et al: Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 558:307–312. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, et al: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 24:1499–1503. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Bonagofski E, Wohlfahrt ME, Pillai SPS and Stephan MT: In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 12:813–820. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Qiu S, Zhang X and Chen W: Optimized DNA electroporation for primary human T cell engineering. Bmc Biotechnol. 18:42018. View Article : Google Scholar : PubMed/NCBI |
